Prevention of REnal and Vascular ENd-stage Disease

The PREVEND Study is a prospective, observational cohort study, focussed to assess the impact of elevated urinary albumin loss in non-diabetic subjects on future cardiovascular and renal disease. PREVEND is an acronym for Prevention of REnal and Vascular ENd-stage Disease. This study started with a population survey on the prevalence of micro-albuminuria and generation of a study cohort of the general population. The goal is to monitor this cohort for the long-term development of cardiac-, renal- and peripheral vascular end-stage disease. For that purpose the participants receive questionnaires on events and are seen every three/four years for a survey on cardiac-, renal- and peripheral vascular morbidity.

Overview

Acronym
PREVEND
Website
PREVEND
Investigators
Dr. Hans Hillege
University of Groningen
Contacts
Dr. Hans Hillege
University of Groningen

General Design

Study design
Cohort
Start - End Year
1997 -
Recruitment Target
  • Individuals
Number of Participants
8,592
Number of Participants with Biological Samples
8,592
Supplementary Information

Of the 85,421 subjects invited 40,856 responded (=48%) . We invited all consenting subjects with a morning urinary albumin concentration (UAC) of >10 mg/L (n=7,768) and an a-select sample of those with an UAC <10 mg/L (n=3,395) for further studies . Of these invitees 8,592 subjects completed the first screening, that was held in 1997/1998

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Marker Papers

Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. J Am Soc Nephrol. 2000 Oct;11(10):1882-8

PUBMED 11004219

Timeline

Population

PREVEND cohort
The Prevend cohort is enriched for the presence of an elevated urinary albumin excretion (UAE). The population is formed of Groningen inhabitants aged 28 to 75 years, who agreed to give a morning urine and to answer a short questionnaire. Of the 85,421 subjects invited to participate, 40,856 responded. The final sample is constisted of 8,592 consenting subjects with a morning urinary albumin concentration (UAC) of >10 mg/L and an a-select sample of those with an UAC <10 mg/L who completed the first screening. Pregnant women and participants with diabetes mellitus were excluded.

Selection Criteria

Minimum age
27
Maximum age
75
Countries
  • Netherlands
Ethnic Origin
  • Caucasian

Sources of Recruitment

General Population
  • Volunteer enrolment

Sample Size

Number of Participants
8,592
Number of Participants with Biological Samples
8,592

Data Collection Events

# Name Data sources Data sources - Biosamples Start End
0 NC1
  • Questionnaires
  • Physical measures
  • Biosamples
  • Blood
  • Urine
1997 1998
1 Second screening
  • Questionnaires
  • Physical measures
  • Biosamples
  • Blood
  • Urine
2001 2003
2 Third screening
  • Questionnaires
  • Cognitive measures
  • Physical measures
  • Biosamples
  • Blood
  • Urine
2003 2006
3 Fourth Screening
  • Questionnaires
  • Physical measures
  • Biosamples
  • Blood
  • Urine
2009 2012

Participating Studies

Acronym Name Study design Countries

Harmonization Initiatives Included

Acronym Name

Datasets

Name Data Collection Events Variables

Areas of Information Collected

Socio-demographic and economic characteristics
Death
Lifestyle and behaviours
Physical measures and assessments
Birth, pregnancy and reproductive health history
Laboratory measures
Perception of health, quality of life, development and functional limitations
Cognition, personality and psychological measures and assessments
Diseases
Life events, life plans, beliefs and values
Symptoms and signs
Preschool, school and work life
Medication and supplements
Social environment and relationships
Non-pharmacological interventions
Physical environment
Health and community care services utilization
Administrative information

Variables Content Summary

Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected

Networks

Acronym Name Harmonization Initiatives Individual Studies
Last Update: 2026-04-27T09:11:12.364